King Pharmaceuticals Aktie

King Pharmaceuticals für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: 911091 / ISIN: US4955821081

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
07.08.2026 15:35:01

Kestrel Group Q2 Slips To Loss From Higher Expenses

(RTTNews) - On Friday, Kestrel Group Ltd (KG), a reinsurance company, reported a slip to a loss in the second quarter of 2026 due to higher expenses against total revenues.

Net loss for the period was $8.08 million or $1.03 per share, compared to net income of $69.93 million or $15.05 per share in the same quarter last year.

Total expenses were $12.99 million, compared to gains of $0.074 million in the previous year.

Adjusted operating losses were $6.74 million or $0.86 per share, compared to the earnings of $5.39 million or $1.12 per share a year ago.

Total Revenues for the period went up to $6.69 million from $5.57 million in the prior year.

On the Nasdaq, the shares were trading at $8.91 with no stock movement.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Nachrichten zu King Pharmaceuticals Inc.

mehr Nachrichten
Keine Nachrichten verfügbar.

Analysen zu King Pharmaceuticals Inc.

mehr Analysen
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!